AYLA News and Press, Ayala Pharmaceuticals Inc. From 01/19/23

REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a biotechnology company devoted to the discovery, development and commercialization of immunotherapies based on a technology which uses engineered Listeria monocytoge...

REHOVOT, Israel and WILMINGTON, Del., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers, today i...

REHOVOT, Israel and WILMINGTON, Del., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers, to...

Ayala Pharmaceuticals press release ( NASDAQ: AYLA ): Q3 GAAP EPS of -$0.66 misses by $0.17 . Revenue of $0.09M (-85.7% Y/Y) misses by $0.51M . Cash Position: Cash and cash equivalents were $11.2 million as of September 30, 2022. Collaboration Revenue...

Entered into a definitive merger agreement with Advaxis Inc. – transaction expected to close by end of Q1 2023, subject to approval by Ayala’s shareholders and the satisfaction of customary closing conditions Interim positive data from Part A of the RINGSIDE study ...

NEW YORK, NY / ACCESSWIRE / October 20, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Aerie Pharmaceuticals, Inc. (NASD...

Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders w...

Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders w...

Event will feature a review of data from part A of the Phase 2/3 RINGSIDE trial of AL102 KOL s and m anagement to p resent on Thursday, October 6 th @ 8 AM ET REHOVOT, Israel and WILMINGTON, Del., Sept. 29, 2...

The U.S. Food and Drug Administration (FDA) granted fast track designation to Ayala Pharmaceuticals' ( NASDAQ: AYLA ) AL102 to treat progressing desmoid tumors. AL102 is being evaluated in a phase 2/3 trial called RINGSIDE, interim results from which were repo...